Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines
T Pilishvili, NM Bennett - Vaccine, 2015 - Elsevier
Use of the pneumococcal conjugate vaccines among children in the US since 2000 has
dramatically reduced pneumococcal disease burden among adults. Significant vaccine …
dramatically reduced pneumococcal disease burden among adults. Significant vaccine …
Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine?
ML Metersky, MT Dransfield, LA Jackson - Chest, 2010 - Elsevier
On February 24, 2010, the US Food and Drug Administration approved a 13-valent
pneumococcal protein conjugate vaccine (PCV13) for use in children. Currently, the only …
pneumococcal protein conjugate vaccine (PCV13) for use in children. Currently, the only …
PCV13 vaccination of adults against pneumococcal disease: what we have learned from the community-acquired pneumonia immunization trial in adults (CAPiTA)
C Theilacker, MA Fletcher, L Jodar, BD Gessner - Microorganisms, 2022 - mdpi.com
The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA) evaluated older
adult pneumococcal vaccination and was one of the largest vaccine clinical trials ever …
adult pneumococcal vaccination and was one of the largest vaccine clinical trials ever …
[HTML][HTML] Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged≥ 65 years: updated …
A Matanock - MMWR. Morbidity and mortality weekly report, 2019 - cdc.gov
Background Streptococcus pneumoniae (pneumococcus) can cause serious illness,
including sepsis, meningitis, and pneumonia with bacteremia (invasive) or without …
including sepsis, meningitis, and pneumonia with bacteremia (invasive) or without …
[HTML][HTML] Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged≥ 65 years: recommendations of …
S Tomczyk, NM Bennett, C Stoecker, R Gierke… - MMWR Morb Mortal …, 2014 - cdc.gov
On August 13, 2014, the Advisory Committee on Immunization Practices (ACIP)
recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar …
recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar …
Pneumococcal vaccination: controversies and opportunities
JS Spika, DS Fedson, RR Facklam - Infectious Disease Clinics of North …, 1990 - Elsevier
The morbidity and mortality associated with pneumococcal infections are preventable in
many high-risk individuals by immunization with 23-valent pneumococcal vaccine. While the …
many high-risk individuals by immunization with 23-valent pneumococcal vaccine. While the …
Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in US older adults
KJ Smith, AR Wateska, MP Nowalk, M Raymund… - American journal of …, 2013 - Elsevier
BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) is approved by
the US Food and Drug Administration for adults, but its role in older adults is unclear …
the US Food and Drug Administration for adults, but its role in older adults is unclear …
Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older
Centers for Disease Control and … - MMWR. Morbidity …, 2012 - pubmed.ncbi.nlm.nih.gov
In 2010, 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth
Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.]) was licensed by the Food and Drug …
Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.]) was licensed by the Food and Drug …
Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial
I Koivula, M Stén, M Leinonen, PH Mäkelä - The American journal of …, 1997 - Elsevier
PURPOSE: To study the efficacy of pneumococcal capsular polysaccharide vaccine among
the elderly by use of a population-based intervention in one township, Varkaus, Eastern …
the elderly by use of a population-based intervention in one township, Varkaus, Eastern …
Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine
KJ Smith, AR Wateska, MP Nowalk, M Raymund… - Jama, 2012 - jamanetwork.com
Context The cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13)
compared with 23-valent pneumococcal polysaccharide vaccine (PPSV23) among US …
compared with 23-valent pneumococcal polysaccharide vaccine (PPSV23) among US …